Our News
29.02
2024
04.01
2024
06.11
2023
01.08
2023
Video interview of our Group CEO, Dimitris Kadis, on Pharmathen’s distinction at the 2022 Growth Awards
03.11
2022
01.08
2022
Our Group CEO, Dimitris Kadis, is featured in Kathimerini special edition “New Challenges, New Horizons”
20.04
2022
Press Release: Pharmathen actively stands by the Ukrainian people, donating medical supplies and basic commodities
08.04
2022
Press Release: Pharmathen’s 200 million euros investment plan, increased by 50 million euros for the next five years period 2022-2026
12.11
2021
29.09
2021
Our participation in CPhI Worldwide 2021!
We are very excited to announce that after a forced break in 2020, we will be exhibiting at the CPhl Worldwide in Milan, from 9th to 11th November 2021
19.07
2021
10.03
2021
Our participation in the digital DIA Europe event!
At Pharmathen, we never miss the opportunity to be a part of DIA Europe, the longest-running event in the life sciences industry
24.02
2021
Donation of a state-of-the-art digital ultrasound processing unit to “Sotiria” General Hospital
As part of our company’s Corporate Social Responsibility initiatives, a state-of-the-art digital ultrasound processing unit was donated to “Sotiria” General Hospital
22.10
2020
Our participation in first virtual CPhI-Festival of Pharma
For yet another year, our team successfully met with our clients during the two-week online gatherings in first virtual CPhI-Festival of Pharma.
28.09
2020
Our participation in the "CPhI: Festival of Pharma" virtual event
For yet another year and under the current restrictions due to the COVID-19 global pandemic, we are excited to participate in the world’s largest exhibition that brings together the global pharmaceutical community
11.06
2020
Pharmathen is among the top 10 “most attractive employers” in Greece in 2020 Randstad Employer Brand Research
Another distinction for our company that has made us very happy. We were selected in the top 10 “most attractive employers" in Greece among a total of 150 companies
15.05
2020
Our actions amid the COVID-19 pandemic
At Pharmathen, despite all difficulties related to the COVID-19 pandemic, we are staying loyal to our values and putting people at the centre of our strategy.
28.04
2020
Pharmathen's voluntary production of antiseptic solutions to meet the emergency needs due to the COVID-19 pandemic
A big “thank you” to our employees who make us proud as they always show responsibility and compassion and do their best to offer to our society and fellow people...
27.04
2020
Press Release by the Panhellenic Union of Pharmaceutical Industries (PEF) regarding Pharmathen’s voluntary participation in producing antiseptic solutions to meet the emergency needs risen due to the COVID-19 pandemic
Following our recent announcement regarding our voluntary production of antiseptic solutions to meet the emergency needs risen due to the COVID-19 pandemic...
27.03
2020
Pharmathen joins forces with the Ministry of Health, the Panhellenic Union of Pharmaceutical Industries and the Greek Army to contribute to Greece's efforts against COVID-19 pandemic
During these critical and unprecedented circumstances for all mankind, Pharmathen and its employees, having as our mission to preserve health, the fundamental asset of all societies, consider as our foremost duty to contribute by all means to the protection of public health and our society.
26.02
2020
08.11
2019
CPhI Worldwide 2019
Participating in CPhI Worldwide 2019 was highly successful for Pharmathen!
06.11
2019
Our company is honored with the “Salus Index Award”!
On Wednesday, the 6th of November 2019, we were honored to receive this year’s “Salus Index Award”.
23.09
2019
Pharmathen is among the finalists for the “Global Generics & Biosimilars Awards 2019”
Pharmathen is delighted to announce that it has been shortlisted as one of the finalists for the “Global Generics & Biosimilars Awards 2019”. These awards aim at rewarding ‘best practice’ in the two industries, while, at the same time, encouraging improvements in every aspect of the way business is conducted.
06.09
2019
Official Launch of the new Long-Acting Injectables Plant by the Minister of Development and Investments, Mr. Adonis Georgiadis
The new plant is part of the company’s total investment plan of over €250 million for the next five years, which will lead to the creation of at least 300 new jobs. Sapes – Rodopi, the 6th of September, 2019. Pharmathen’s new Long-Acting Injectables Unit was officially launched today by the Minister of Development and Investments, Mr. Adonis Georgiadis; during a ceremony attended by representatives of the central and local government, the scientific and business community, and the Media.
02.09
2019
CPHI 2019
For yet another year, Pharmathen participates in CPhI Worldwide exhibition 2019 in Frankfurt @Stand No 80C72.
11.07
2019
Pharmathen is among the “Diamonds of the Greek Economy 2019”
For yet another year, we received the “Diamonds of the Greek Economy” distinction at the business...
11.06
2019
Pharmathen’ s distinction for its “Business Extroversion” for yet another year!
Another great distinction for our company!
17.05
2019
Our legal team is in the “Legal 500 2019 General Counsel Powerlist: Greece & Cyprus”.
We are proud of our legal team’s distinction to be among the “Legal 500 2019 General Counsel Powerlist: Greece & Cyprus” that were honored in a reception that took place in Athens on 16 May 2019.
30.04
2019
More investments in Northern Greece!
Pharmathen proceeded to new investments and acquired an additional 27-acres land in the Industrial Park of Sapes in order to expand its innovative business.
27.02
2019
Pharmathen’s 50 years Anniversary: A brilliant history; an even brighter future!
Pharmathen’s press event for its 50-years milestone
31.01
2019
Celebrating our 50-years Anniversary!
Coming together from all around the globe, we celebrated with our people 50 years of operation...
04.01
2019
Pharmathen ranked 1st among Greek companies investing in R&D based on the 2018 EU Industrial R&D Investment Scoreboard.
For yet another year, Pharmathen has been distinguished at the “2018 EU Industrial R&D Investment Scoreboard” and is ranked first among Greek companies based on R&D spending, by investing 33% of its turnover. With annual R&D spending of 49.9 million euros in the 2017-2018 period, Pharmathen ranked 396th on this year’s list of 1,000 companies in the EU with the highest R&D expenditure.
11.10
2018
CPhI Worldwide exhibition, Madrid
Our participation in CPhI 2018 Worldwide, the world's largest pharmaceutical exhibition, has been a great opportunity for our executives to meet and interact with hundreds of customers and partners coming from around the globe.
04.10
2018
CPHI 2018
For yet another year, Pharmathen participates at CPHI 2018 in Madrid @Stand No 9F31. We look forward to see you there!
01.12
2017
Pharmathen sells its commercial operations in Greece to focus exclusively on international markets
Amsterdam, 30/11/2017: Pharmathen, a BC Partners portfolio company, announces the sale of its Greek commercial operations as part of its long-term strategy to become a leader focused on the development of innovative and complex pharmaceuticals.
31.10
2017
Impressive presence by Pharmathen in CPhI 2017
For yet another year, Pharmathen had an impressive presence at the international exhibition CPhI Worldwide 2017 which took place in Frankfurt, Germany on the 24-26 October 2017.
02.06
2015
The significant investment by BC Partners opens new perspectives for Pharmathen
The Management of Pharmathen announces the signing of a partnership agreement in principle for the acquisition of a majority stake of shares of the Group from the investment group BC Partners. Katsos family remains in the Pharmathen Group, keeping a significant stake of shares and the management of the group.
09.12
2014
Ranking even Higher among Companies that are Distinguished for their Investments in Research
Ranking even higher among companies that are distinguished for their investments in Research on the basis of the 2014 EU Industrial R&D Investment Scoreboard.
27.11
2014
Τhe First Private Greek Company to be Funded by the European Investment Bank (EIB)
The first funding provided to a private Greek company by the European Investment Bank - ΕΙΒ has been secured by Pharmathen to support its programme concerning the Research and Development of innovative products.
18.06
2014
LAI Technology: Breakthrough Innovation by Pharmathen
The Greek Pharmaceutical Industry Pharmathen has taken its place on the world map of innovation in the pharmaceutical field, following the most recent achievement by the department of Research and Development of innovative healthcare products, that concerns the development of Long Acting Injectable (LAI) Technology – sustained-release injectable products.